On Friday, Shares of Alphabet Inc (NASDAQ:GOOGL) added 0.06% and closed at $804.60 in the last trading session. The last trading range of the stock ranges between $802.32 and $810.09. Alphabet Inc., through its auxiliaries, provides online advertising services in the United States, the United Kingdom, and rest of the world. The company offers performance and brand advertising services. It operates through Google and Other Bets segments. The Google segment includes principal Internet products, such as Search, Ads, Commerce, Maps, YouTube, Apps, Cloud, Android, Chrome, and Google Play, in addition to technical infrastructure and newer efforts, such as Virtual Reality. This segment also sells hardware products comprising Chromecast, Chromebooks, and Nexus.
Seattle Genetics, Inc. (NASDAQ:SGEN) lost -3.79% and closed at $50.31 in the last trading session. The last trading range of the stock ranges between $50.29 and $53.06. Seattle Genetics, Inc., a biotechnology company, develops and commercializes targeted therapies for the treatment of cancer worldwide. It markets ADCETRIS (brentuximab vedotin), an antibody-drug conjugate for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. The company also develops SGN-CD33A, which is in Phase 1b trial for patients with newly diagnosed acute myeloid leukemia (AML); Phase 1/2 trial for patients with relapsed or refractory AML; Phase 1/2 trial for patients with formerly untreated myelodysplastic syndrome; and Phase 1 trial for patients with AML. In addition, it is developing SGN-CD19A that is in Phase 2 trials for patients with relapsed or refractory diffuse large B-cell lymphoma, in addition to in Phase 1 trial for relapsed or refractory B-cell non-Hodgkin lymphomas, and relapsed or refractory B-cell acute lymphoblastic leukemia; SGN-LIV1A, which is in Phase 1 trial for the treatment of LIV-1-positive metastatic breast cancer; SGN-CD70A that is in Phase 1 trial for the treatment of CD70-positive renal cell carcinoma; SEA-CD40, which is in Phase 1 trial for the treatment of CD40-positive solid tumors; ASG-22ME that is in Phase 1 trial for the treatment of Nectin-4-positive solid tumors, counting bladder cancer; and ASG-15ME, which is in Phase 1 trial for the treatment of bladder cancer.